Results from phase IIIb trials demonstrate rapid and long-lasting effect of RelabotulinumtoxinA on crow’s feet and frown lines.- Galderma

Both studies met their primary endpoints, demonstrating that RelabotulinumtoxinA, a novel liquid formulation botulinum toxin A, significantly improves both frown lines and crow’s feet, with a rapid onset of action as early as day one and long duration.

“These results provide an additional layer of confidence in the long-lasting efficacy, speed and convenience of RelabotulinumtoxinA, which not only represents the innovation of our neuromodulator portfolio, but also demonstrates our commitment to responding to the real needs of healthcare professionals and patients.”

3QM2106 is a phase IIIb, randomized, double-blind, placebo-controlled trial to assess the aesthetic improvement and onset of action of RelabotulinumtoxinA in patients with moderate to severe frown lines . The trial met its primary endpoint, with 92.9% of those treated with RelabotulinumtoxinA rating their frown lines as ‘improved’ or better on the Global Aesthetic Improvement Scale (GAIS) at month one, compared to 9.1% of those treated with placebo (P<0.001).></0.001).>

Results reinforced the rapid onset of action and durability of RelabotulinumtoxinA, with 40% of patients rating themselves as ‘improved’ or better on the GAIS as early as day one, and more than a third (38%) of patients rating themselves as ‘improved’ or better at month 12. In addition, 68% and 43% of patients rated themselves as ‘improved’ or better at months six and nine respectively, and 40% of patients also reported at least a one grade improvement of frown line severity at month nine. RelabotulinumtoxinA was well tolerated; the majority of patients did not experience any adverse events and there were no related serious adverse events reported.

43QM2107 is a phase IIIb, open-label, single-center study to assess aesthetic improvement of RelabotulinumtoxinA in patients with moderate to severe crow’s feet and frown lines. It also met its primary endpoint, with 100% of patients treated with RelabotulinumtoxinA rating their crow’s feet and frown lines as ‘improved’ or better on the GAIS at month one. RelabotulinumtoxinA demonstrated a rapid onset of action for both crow’s feet and frown lines, with the majority of patients (68% and 60% for crow’s feet and frown lines, respectively) rating themselves as ‘improved’ or better on the GAIS starting at day one. By day two, 100% of patients noted improvement for crow’s feet and 96% noted improvement for frown lines. This was reinforced by Subject Live Assessment results using a validated scale, which showed that 40% of patients on day one and 96% of patients on day four received a score of zero or one on a four-point scale for crow’s feet severity at maximum expression. For frown line severity, 32% of patients on day one and 92% of patients on day four received a score of zero or one.

RelabotulinumtoxinA was well tolerated, with no adverse events reported in 92% of patients.

Results from both studies are in line with those previously seen for RelabotulinumtoxinA.